Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547567 | 0.87 | L3MBTL1 (0.59) | L3MBTL1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL2319403 | 0.87 | CA1 (0.48) | TSHRKMT2AALDH1A1GAACA12 | |
| SCHEMBL9698386 | 0.80 | NR5A1 (0.47) | L3MBTL1TSHRKMT2AALDH1A1MAPT | |
| SCHEMBL9699724 | 0.80 | NR5A1 (0.47) | L3MBTL1TSHRKMT2AALDH1A1MAPT | |
| SCHEMBL34475986 | 0.79 | ALDH1A1 (0.45) | L3MBTL1TSHRKMT2AALDH1A1GAA | |
| SCHEMBL12129099 | 0.79 | KDM4E (0.62) | L3MBTL1TSHRKMT2AGAAMAPT | |
| SCHEMBL1835919 | 0.79 | ALDH1A1 (0.45) | L3MBTL1TSHRKMT2AALDH1A1GAA | |
| SCHEMBL11336303 | 0.79 | L3MBTL1 (0.49) | L3MBTL1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL8072909 | 0.79 | ALDH1A1 (0.49) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL2525928 | 0.79 | L3MBTL1 (0.62) | L3MBTL1KMT2AALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
| EP-0118377-B1 | PROCESS FOR THE PRODUCTION OF METACHLORINATED PHENOLS | RHONE-POULENC CHIMIE (FR) | 1988-03-09 | — | — | EP | disclosed |
| US-4540834-A | HYDRODECHLORINATION OF POLYCHLOROPHENOL, HYDRIOTIC ACID | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-09-10 | — | — | US | disclosed |
| EP-0118377-A2 | Process for the production of metachlorinated phenols | RHONE-POULENC CHIMIE (FR) | 1984-09-12 | — | — | EP | disclosed |
| EP-0055196-B1 | PROCESS FOR THE SYNTHESIS OF METACHLOROPHENOLS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-04-18 | — | — | EP | disclosed |
| EP-0055198-B1 | PROCESS FOR THE SYNTHESIS OF METACHLOROPHENOLS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-04-04 | — | — | EP | disclosed |
| EP-0055197-B1 | PROCESS FOR THE SYNTHESIS OF METACHLOROPHENOLS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-04-04 | — | — | EP | disclosed |
| US-4410738-A | Preparation of meta-chlorophenols by selective hydrodechlorination of polychlorophenols | RHONE-POULENC INDUSTRIES (FR) | 1983-10-18 | — | — | US | disclosed |
| US-4410737-A | Preparation of meta-chlorophenols by selective hydrodechlorination of polychlorophenols | RHONE-POULENC INDUSTRIES (FR) | 1983-10-18 | — | — | US | disclosed |
| US-4410739-A | LEWIS ACID, NOBLE METAL CATALYST | RHONE-POULENC INDUSTRIES (FR) | 1983-10-18 | — | — | US | disclosed |
| EP-0055197-A1 | Process for the synthesis of metachlorophenols | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-06-30 | — | — | EP | disclosed |
| EP-0055196-A1 | Process for the synthesis of metachlorophenols | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-06-30 | — | — | EP | disclosed |
| EP-0055198-A1 | Process for the synthesis of metachlorophenols | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | L3MBTL1 3633/4885TSHR 3672/4885KMT2A 3249/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | L3MBTL1 2780/4885TSHR 4580/4885KMT2A 828/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | L3MBTL1 3961/4885TSHR 3645/4885KMT2A 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.